Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 32, 2002 - Issue 3
Submit an article Journal homepage
67
Views
13
CrossRef citations to date
0
Altmetric
Research Article

SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: In vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man

K. W. Ward Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery
,
J. W. Proksch Drug Metabolism and Pharmockinetics, GlaxoSmithKline R & D, King of Prussia, PA 19406, USA
,
P. D. Gorycki Drug Metabolism and Pharmockinetics, GlaxoSmithKline R & D, King of Prussia, PA 19406, USA
,
C.-P. Yu Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery
,
M. Y. K. Ho Drug Metabolism and Pharmockinetics, GlaxoSmithKline R & D, King of Prussia, PA 19406, USA
,
B. D. Bush Drug Metabolism and Pharmockinetics, GlaxoSmithKline R & D, King of Prussia, PA 19406, USA
,
M. A. Levy Preclinical Drug Discovery, Cardiovascular, Urogenitary, and Oncology Centre for Excellence in Drug Discovery
&
B. R. Smith Drug Metabolism and Pharmockinetics, GlaxoSmithKline R & D, King of Prussia, PA 19406, USA
 show all
Pages 235-250 | Published online: 22 Sep 2008

References

  • BADGER, A. M., GRISWOLD, D. E., KAPADIA, R., BLAKE, S., SWIFT, B. A., HOFFMAN, S. J., STROUP, G. B., WEBB, E., RIEMAN, D. J., GOWEN, M., BOEHM, J. C., ADAMS, J. L. and LEE, J. C., 2000, Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced disease. Arthritis Rheumatism, 43, 175–183.
  • BOXENBAUM, H., 1982, Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmacology, 10, 201–227.
  • DAVIES, B. and MORRIS, T., 1993, Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093–1095.
  • EKINS, S., MÄENPAA, J. and WRIGHTON, S. A., 1999, In vitro metabolism: subcellular fractions. In T. W. Woolf (ed.), Handbook of Drug Metabolism (New York: Marcel Dekker), pp 363–399.
  • FULLERTON, T., SHARMA, A., PRABHAKAR, U., TUCCI, M., BOIKE, S. and DAVIS, H,. 2000, Suppression of ex vivo cytokine production by SB 242235, a selective inhibitor of p38 MAP kinase. Clinical and Pharmacological Therapeutics, 114 (Meeting Abstract).
  • HOWARD, M. O., NEWTON, J. F., KOHANE, D. J., YODIS, L. P., SAVERINO, C. M., QUALLS, C. W., JR, and SCHWARTZ, L. W., 1990, In vitro metabolism of the novel antiinflamrnatory agent 6-(4' fluoro phenyl) - 5 -(4' -pyridy1)-2,3- dihydroimidazo- {2,1 -b} -thiazole.Drug Metabolism andDisposition, 18, 607–612.
  • KIM, S. H., KIM, W. B. and LEE, M. G., 1998, Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharmacology and Drug Disposition, 19, 231–235.
  • LEE, J. C., Kassis, S., KUMAR, S., BADGER, A. and ADAMS, J. L., 1999, p38 Mitogen-activated protein kinase inhibitors—mechanisms and therapeutic potentials. Pharmacological Therapeutics, 82, 389–397.
  • LEE, J. C., KUMAR, S., GRISWOLD, D. E., UNDERWOOD, D. C., VOTTA, B. J. and ADAMS, J. L., 2000, Inhibition of p38 MAP kinase as a therapeutic strategy. /mmunopharmaco/ogy, 47, 185–201.
  • MAHMOOD, I., 1998, Interspecies scaling of renally secreted drugs. Life Sciences, 63, 2365–2371.
  • MAHMOOD, I., 1999, Allometric issues in drug development. Journal of Pharmaceutical Sciences, 11, 1101–1106.
  • MAHMOOD, I. and BALIAN, J. D., 1996, Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica, 26, 887–895.
  • NEWTON, J. F., YODIS, L. P., KEOHANE, D., ECKARDT, R., DEWEY, R., DENT, J. and Mico, B., 1989, Pharmacokinetics and metabolism of SK&F 86002 in male and female Sprague—Dawley rats. Drug Metabolism and Disposition, 17, 174–179.
  • PARRISH, A. R., GANDOLFI, A. J. and BRENDEL, K., 1995, Precision-cut tissue slices: applications in pharmacology and toxicology. Life Sciences, 57, 1887–1901.
  • RITSCHEL, W. A., VACHHARAJANI, N. N., JOHNSON, R. D. and HUSSAIN, A. S., 1992, The allometric approach for interspecies scaling of pharmacokinetic parameters. Computers in Biological Physics, 103C, 249–253.
  • STEIN, B. and ANDERSON, D., 1996, The MAP kinase family: New `MAPs' for signal transduction pathways and novel targets for drug discovery. Annals in the Reporting of Medical Chemistry, 31, 289–298.
  • TIMCHALK, C. and NOLAN, R. J., 1997, Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human. Toxicology and Applied Pharmacology, 144, 268–278.
  • UNDERWOOD, D. C., OSBORN, R. R., KOTZER, C. J., ADAMS, J. L., LEE, J. C., WEBB, E. F., CARPENTER, D. C., BOCHNOWICZ, S., THOMAS, H. C., HAY, D. W. P. and GRISWOLD, D. E., 2000, SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. Journal of Pharmacology and Experimental Therapeutics, 293, 281–288.
  • VAN HOOGDALEM, E. J., SOE ISHI, Y., MATSUSHIMA, H. and HI GUCHI, S., 1997, Disposition of the selective (1A-adrenoceptor antagonist tamsulosin in humans: Comparison of data from interspecies scaling. Journal of Pharmaceutical Science, 86, 1156–1161.
  • WARD, K. W., PROKSCH, J. W., SALYERS, K. L., AZZARANO, L. M., MORGAN, J. A., ROETHKE, T. J., MCS URDY- FREED, J. E., LEVY, M. A. and SMITH, B. R., 2002, SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I. Preclinical pharmacokinetics. Xenobiotica, 32, 221–233.
  • WELLING, P. G., 1993, Pharmacokinetic principles. Linear and nonlinear. In P. G. Welling (ed.), Drug Toxicokinetics (New York: Marcel Dekker), pp. 19–42.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.